MedTrace Logo

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

NCT01611272 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3402

Last updated 2017-07-13

No results posted yet for this study

Summary

To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.

Conditions

  • Acute Coronary Syndromes

Sponsors & Collaborators

Principal Investigators

  • JooWon Lee · AstraZeneca Korea

Eligibility

Min Age
19 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-07-20
Completion
2016-07-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01611272 on ClinicalTrials.gov